Trevi Therapeutics, Inc. (TRVI) Operating income 2018–2025
Trevi Therapeutics, Inc. (TRVI) annual operating income history from SEC filings — each fiscal year as reported.
-$49.3MFY2025 · since FY2018: -$18.4M → -$49.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$49.3M | +4.3% |
| FY2024 | -$51.5M | -51.9% |
| FY2023 | -$33.9M | -13.4% |
| FY2022 | -$29.9M | +7.9% |
| FY2021 | -$32.5M | +0.0% |
| FY2020 | -$32.5M | -21.9% |
| FY2019 | -$26.6M | -44.7% |
| FY2018 | -$18.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TRVI financial trends
TRVI RevenueTRVI Net incomeTRVI Net marginTRVI Gross profitTRVI Gross marginTRVI Operating marginTRVI Operating cash flowTRVI Free cash flowTRVI Capital expendituresTRVI Return on equityTRVI Stock buybacksTRVI Dividends paidTRVI Total assetsTRVI Total liabilitiesTRVI Shareholders’ equityTRVI overview →